Cambridge Cognition CEO Dr Matthew Stork ‘Strategy paying off’ with significant new contract win (Interview)

Cambridge Cognition plc (LON:COG) CEO Dr Matthew Stork joins DirectorsTalk to discuss a contract win for three phase II studies with a new pharmaceutical client. Matthew provides us with some background on the company and its business model, provides more details around the win and what it means strategically and the effects the company is seeing with regards to Covid-19.

Cambridge Cognition is a neuroscience technology company developing digital health products to better understand, detect and treat conditions affecting brain health. The company’s software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early and improve global efficiency in pharmaceutical and healthcare industries.

You might also enjoy reading  Cabot Oil & Gas Corporation - Consensus Indicates Potential 10.0% Upside
Find more news, interviews, share price & company profile here for:
Cambridge Cognition Holdings plc

Share this interview

Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on facebook
Facebook
Share on email
Email
Share on whatsapp
WhatsApp
Neuroscience Technology
Cambridge Cognition CEO Dr Matthew Stork ‘Strategy paying off’ with significant new contract win (Interview)

Other Interviews

More News

Ask your questions

Do you have questions you’d like to ask this company, get in touch and we’ll ask them for you.   

I have questions